These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
900 related articles for article (PubMed ID: 29764864)
1. Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer. Moses MA; Kim YS; Rivera-Marquez GM; Oshima N; Watson MJ; Beebe KE; Wells C; Lee S; Zuehlke AD; Shao H; Bingman WE; Kumar V; Malhotra SV; Weigel NL; Gestwicki JE; Trepel JB; Neckers LM Cancer Res; 2018 Jul; 78(14):4022-4035. PubMed ID: 29764864 [TBL] [Abstract][Full Text] [Related]
2. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer. Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515 [No Abstract] [Full Text] [Related]
3. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor. Patki M; Huang Y; Ratnam M Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779 [TBL] [Abstract][Full Text] [Related]
4. Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells. Dong J; Wu Z; Wang D; Pascal LE; Nelson JB; Wipf P; Wang Z Mol Cancer Ther; 2019 Jan; 18(1):39-50. PubMed ID: 30297360 [TBL] [Abstract][Full Text] [Related]
5. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7). Lin SJ; Chou FJ; Li L; Lin CY; Yeh S; Chang C Cancer Lett; 2017 Jul; 398():62-69. PubMed ID: 28373004 [TBL] [Abstract][Full Text] [Related]
6. Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer. Yang YC; Banuelos CA; Mawji NR; Wang J; Kato M; Haile S; McEwan IJ; Plymate S; Sadar MD Clin Cancer Res; 2016 Sep; 22(17):4466-77. PubMed ID: 27140928 [TBL] [Abstract][Full Text] [Related]
7. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Shafi AA; Yen AE; Weigel NL Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer. Singh KB; Ji X; Singh SV Mol Cancer Ther; 2018 Oct; 17(10):2079-2090. PubMed ID: 30030299 [TBL] [Abstract][Full Text] [Related]
10. Downregulation of Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112 [TBL] [Abstract][Full Text] [Related]
11. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer. Thamilselvan V; Menon M; Thamilselvan S Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552 [TBL] [Abstract][Full Text] [Related]
12. Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models. Xu P; Yang JC; Ning S; Chen B; Nip C; Wei Q; Liu L; Johnson OT; Gao AC; Gestwicki JE; Evans CP; Liu C Pharmacol Res; 2023 Mar; 189():106692. PubMed ID: 36773708 [TBL] [Abstract][Full Text] [Related]
13. Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents. Zhang G; Liu X; Li J; Ledet E; Alvarez X; Qi Y; Fu X; Sartor O; Dong Y; Zhang H Oncotarget; 2015 Sep; 6(27):23358-71. PubMed ID: 26160840 [TBL] [Abstract][Full Text] [Related]
14. Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer. Kato M; Banuelos CA; Imamura Y; Leung JK; Caley DP; Wang J; Mawji NR; Sadar MD Clin Cancer Res; 2016 Jun; 22(11):2744-54. PubMed ID: 26712685 [TBL] [Abstract][Full Text] [Related]
15. ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. Cato L; de Tribolet-Hardy J; Lee I; Rottenberg JT; Coleman I; Melchers D; Houtman R; Xiao T; Li W; Uo T; Sun S; Kuznik NC; Göppert B; Ozgun F; van Royen ME; Houtsmuller AB; Vadhi R; Rao PK; Li L; Balk SP; Den RB; Trock BJ; Karnes RJ; Jenkins RB; Klein EA; Davicioni E; Gruhl FJ; Long HW; Liu XS; Cato ACB; Lack NA; Nelson PS; Plymate SR; Groner AC; Brown M Cancer Cell; 2019 Mar; 35(3):401-413.e6. PubMed ID: 30773341 [TBL] [Abstract][Full Text] [Related]
16. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436 [TBL] [Abstract][Full Text] [Related]
17. Heat shock protein 70 inhibitors suppress androgen receptor expression in LNCaP95 prostate cancer cells. Kita K; Shiota M; Tanaka M; Otsuka A; Matsumoto M; Kato M; Tamada S; Iwao H; Miura K; Nakatani T; Tomita S Cancer Sci; 2017 Sep; 108(9):1820-1827. PubMed ID: 28691182 [TBL] [Abstract][Full Text] [Related]
18. Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer. Dalal K; Ban F; Li H; Morin H; Roshan-Moniri M; Tam KJ; Shepherd A; Sharma A; Peacock J; Carlson ML; LeBlanc E; Perez C; Duong F; Ong CJ; Rennie PS; Cherkasov A Cancer Lett; 2018 Nov; 437():35-43. PubMed ID: 30165195 [TBL] [Abstract][Full Text] [Related]
19. Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC). Welti J; Sharp A; Yuan W; Dolling D; Nava Rodrigues D; Figueiredo I; Gil V; Neeb A; Clarke M; Seed G; Crespo M; Sumanasuriya S; Ning J; Knight E; Francis JC; Hughes A; Halsey WS; Paschalis A; Mani RS; Raj GV; Plymate SR; Carreira S; Boysen G; Chinnaiyan AM; Swain A; de Bono JS; Clin Cancer Res; 2018 Jul; 24(13):3149-3162. PubMed ID: 29555663 [No Abstract] [Full Text] [Related]
20. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model. Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]